View Older Stories
-
Hologic (HOLX) PT Raised to $76 at Morgan Stanley
-
Needham Reiterates Hold Rating on Hologic (HOLX)
-
Hologic (HOLX) Tops Q4 EPS by 3c
-
Mizuho Downgrades Hologic (HOLX) to Neutral
-
Stephens Downgrades Hologic (HOLX) to Equal Weight
-
JPMorgan Downgrades Hologic (HOLX) to Neutral
-
Hologic (HOLX) call put ratio 1.4 calls to 1 put after acquired by Blackstone & TPG for $18.3B
-
Hologic (HOLX) to Resume Trading at 9 a.m.
-
Blackstone and TPG to acquire Hologic for up to $79 per share
-
Hologic (HOLX) Halted, News Pending
-
Blackstone, TPG Are Said To Near Deal To Acquire Hologic (HOLX) - Bloomberg
-
Needham Reiterates Hold Rating on Hologic (HOLX)
-
Hologic (HOLX) call put ratio 4.6 calls to 1 put with a focus on November calls
-
Evercore ISI Upgrades Hologic (HOLX) to Outperform
-
VolitionRx signs co-marketing deal with Hologic for discovery service
-
Minicarm.com becomes exclusive US distributor for Hologic imaging system
-
Hologic (HOLX) call put ratio 2.2 calls to 1 put into Bloomberg report of PE interest
-
Blackstone, TPG Are Said To Revive Interest In Hologic (HOLX) Takeover - Bloomberg
-
BTIG Reiterates Neutral Rating on Hologic (HOLX)
-
Argus Upgrades Hologic (HOLX) to Buy
-
RBC Capital Upgrades Hologic (HOLX) to Outperform
-
Hologic (HOLX) PT Raised to $75 at Mizuho
-
Hologic (HOLX) Tops Q3 EPS by 3c; offers guidance
-
Citi Upgrades Hologic (HOLX) to Buy, 'possibility/likelihood of being taken out in a private transaction'
-
Supreme Court Braidwood ruling is positive for DX names like DHR, EXAS, NTRA, HOLX, QDEL - RBC Capital
-
Supreme Court Braidwood ruling is positive for Exact Sciences (EXAS) and Hologic (HOLX)
-
Hologic (HOLX) Shares Spike Following Halt
-
Hologic (HOLX) PT Lowered to $70 at Stephens
-
Hologic (HOLX) PT Lowered to $65 at Mizuho
-
Hologic (HOLX) PT Lowered to $65 at Jefferies
-
Hologic (HOLX) Tops Q2 EPS by 1c; offers guidance
-
Hologic (HOLX) Appoints Wayde McMillan to its Board
-
Hologic (HOLX) Announces FDA Clearance of Aptima SARS-CoV-2 Assay
-
Hologic (HOLX) PT Lowered to $83 at Mizuho
-
Needham Reiterates Hold Rating on Hologic (HOLX)
-
Hologic (HOLX) Tops Q1 EPS by 2c, provides guidance
-
Needham Downgrades Hologic (HOLX) to Hold
-
Hologic (HOLX) Completes Acquisition of Gynesonics
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Stephens Reiterates Overweight Rating on Hologic (HOLX)
-
Hologic (HOLX) Statement on USPSTF Draft Cervical Cancer Screening Guidelines
-
Hologic (HOLX): Martin Madaus Elected Board of Directors
-
Jefferies Starts Hologic (HOLX) at Hold
-
Hologic (HOLX) PT Lowered to $87 at Mizuho
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Hologic (HOLX) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 EPS Guidance
-
FDA Issues Alert on Hologic’s (HOLX) BioZorb Markers
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Hologic (HOLX) to Acquire Gynesonics
-
Hologic (HOLX) PT Raised to $90 at Mizuho

